Skip to main content
Defiance International

Study type: Human research · Status: Evidence verified by machine against declared source

Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage.

BMC neurology · 2020

Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Product or molecular entity relationships

  • Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Public plain-language summary

Some fields are not published, because the text held for them did not answer their heading. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Global functional outcome was evaluated by an independent assessor, a registered nurse, at 30 days, 3 months and 6 months after ictus using the following instruments: the Extended Glasgow Outcome Scale (GOSE), mRS and BI.

Study design

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Participants or experimental system

Cerebrolysin (EVER Neuro Pharma GmbH, Unterach, Austria) is an intravenously administered preparation of low-molecular weight neuropeptides of less than 10 kDa (80%) and free amino acids (20%) derived from porcine brain tissue.

Study scale

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.